Suppr超能文献

巴西草药药品市场与新法规对传统药物的影响。

The Brazilian market of herbal medicinal products and the impacts of the new legislation on traditional medicines.

机构信息

Gerência Geral de Medicamentos. Agência Nacional de Vigilância Sanitária (Anvisa), SIA, Trecho 5, Área Especial 57, Brasília 71205-050, DF, Brazil.

Laboratório de Controle da Qualidade, Faculdade de Ciências da Saúde, Universidade de Brasília (UnB). Campus Universitário Darcy Ribeiro, Asa Norte, Brasília 70810-900, DF, Brazil.

出版信息

J Ethnopharmacol. 2018 Feb 15;212:29-35. doi: 10.1016/j.jep.2017.09.040. Epub 2017 Oct 4.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

the herbal medicinal products (HMP) market is expanding in the world, an expansion that has not occurred in Brazil when considering the number of licensed products. Despite being a megadiverse country, the number of HMP licensed in Brazil is small, and the number of HMP obtained from native species is even smaller. A new legislation for herbal products licensing, which divides the products into two categories, Herbal Medicine (HM) and Traditional Herbal Product (THP) was launched in Brazil focusing on traditional use, as well as a law regulating the use of biodiversity and traditional knowledge.

AIM OF THE STUDY

to evaluate the situation of HMP licensed in Brazil and to make a comparison with the data obtained in 2008 and 2011, discussing the evolution of the licensed products and the possible impacts of the new legislation.

MATERIALS AND METHODS

a survey was carried out in the Brazilian Health Regulatory Agency (Anvisa) database to verify the HMP licensed in Brazil in September 2016. The data obtained were compared with two surveys previously published.

RESULTS

There are 332 single, and 27 combined HM, totaling 359 HM licensed in Brazil. There is no THP notified in Anvisa's system yet. There are 214 HM classified as nonprescription (OTC), while 145 are sold under prescription, one of them with prescription retention. There are 101 plant species licensed as active in HM in Brazil, 39 of which are native, adapted or cultivated. The most licensed plant species is Mikania glomerata Spreng., with 25 HM licensed. The article includes tables with plant species that have derivatives licensed as simple and combined HM, their therapeutic classification, the native plant species indication and the distribution of the companies by Brazilian regions.

CONCLUSIONS

There are few licensed HM in Brazil, and this number has been decreasing in recent years. It is expected that the data obtained, together with the changes promoted in sanitary and environmental rules, will help to develop and regulate HMP chain in Brazil.

摘要

民族药理学相关性

草药医药产品(HMP)市场在全球范围内不断扩大,而在考虑已许可产品数量的情况下,巴西并未出现这种扩张。尽管巴西是一个拥有大量生物多样性的国家,但在巴西获得许可的 HMP 数量很少,而从本地物种中获得的 HMP 数量就更少了。巴西推出了一项新的草药产品许可法规,将产品分为草药医药(HM)和传统草药产品(THP)两类,侧重于传统用途,以及一项规范生物多样性和传统知识使用的法律。

研究目的

评估在巴西获得许可的 HMP 情况,并与 2008 年和 2011 年获得的数据进行比较,讨论许可产品的演变以及新法规的可能影响。

材料和方法

在 2016 年 9 月,对巴西卫生监管机构(Anvisa)数据库进行了一项调查,以核实在巴西获得许可的 HMP。所获得的数据与之前公布的两项调查进行了比较。

结果

巴西共有 359 种单一和 27 种组合的 HM 获得许可,其中没有 THP 在 Anvisa 的系统中被通报。有 214 种 HM 被归类为非处方(OTC),而 145 种则凭处方销售,其中一种保留处方。在巴西,有 101 种植物物种被许可为 HM 的活性成分,其中 39 种为本地、适应或栽培的植物。被许可的植物物种中最常见的是 Mikania glomerata Spreng.,有 25 种 HM 获得许可。本文还包括了植物物种的表格,这些植物物种的衍生产品被许可为单一和组合的 HM,其治疗分类,本地植物物种的指示以及巴西各地区的公司分布情况。

结论

巴西获得许可的 HM 数量较少,近年来数量一直在减少。预计所获得的数据以及卫生和环境法规的变化将有助于在巴西发展和规范 HMP 链。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验